Publications 2019

Lilleby O, Hernes E, Lilleby W (2019)
Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
Urol Case Rep, 27, 100992
DOI 10.1016/j.eucr.2019.100992, PubMed 31453108

Rusten E, Rekstad BL, Undseth C, Klotz D, Hernes E, Guren MG, Malinen E (2019)
Anal cancer chemoradiotherapy outcome prediction using ¹⁸F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
Br J Radiol, 92 (1097), 20181006
DOI 10.1259/bjr.20181006, PubMed 30810343

Publications 2017

Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
Dynamic 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
Mol Imaging Biol, 19 (2), 271-279
DOI 10.1007/s11307-016-0998-x, PubMed 27541026

Rusten E, Rekstad BL, Undseth C, Al-Haidari G, Hanekamp B, Hernes E, Hellebust TP, Malinen E, Guren MG (2017)
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Radiat Oncol, 12 (1), 147
DOI 10.1186/s13014-017-0883-z, PubMed 28874205

Publications 2014

Nome R, Hernes E, Bogsrud TV, Bjøro T, Fosså SD (2014)
Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223
Scand J Urol, 49 (3), 211-7
DOI 10.3109/21681805.2014.982169, PubMed 25515952

Publications 2013

Fosså SD, Nilssen Y, Kvåle R, Hernes E, Axcrona K, Møller B (2013)
Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience
Urology, 83 (1), 146-52
DOI 10.1016/j.urology.2013.08.081, PubMed 24238563

Publications 2012

Kyrdalen AE, Dahl AA, Hernes E, Småstuen MC, Fosså SD (2012)
A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer
BJU Int, 111 (2), 221-32
DOI 10.1111/j.1464-410X.2012.11198.x, PubMed 22672151

Publications 2010

Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fosså SD (2010)
Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy
Prostate Cancer Prostatic Dis, 13 (2), 144-50
DOI 10.1038/pcan.2009.61, PubMed 20101260

Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fosså SD (2010)
Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs
Prostate, 70 (13), 1480-9
DOI 10.1002/pros.21183, PubMed 20687221

Publications 2009

Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Axcrona K, Fosså SD (2009)
Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry
BJU Int, 105 (6), 805-11; discussion 811
DOI 10.1111/j.1464-410X.2009.08834.x, PubMed 19735258

Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE (2009)
Association between serum 25(OH)D and death from prostate cancer
Br J Cancer, 100 (3), 450-4
DOI 10.1038/sj.bjc.6604865, PubMed 19156140

Tretli S, Kvåle R, Hernes E (2009)
[Unreliable survival analysis]
Tidsskr Nor Laegeforen, 129 (5), 429-30; author reply 430
DOI 10.4045/tidsskr.08.0679, PubMed 19247405

Publications 2008

Hernes E, Johansson LA, Fosså SD, Pedersen AG, Glattre E (2008)
High prostate cancer mortality in Norway evaluated by automated classification of medical entities
Eur J Cancer Prev, 17 (4), 331-5
DOI 10.1097/CEJ.0b013e3282f5220d, PubMed 18562957

Kvåle R, Hernes E, Bray F (2008)
Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73
Eur Urol, 55 (5), e88-9; author reply e90-1
DOI 10.1016/j.eururo.2008.11.036, PubMed 19062155

Publications 2007

Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F (2007)
Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries
J Natl Cancer Inst, 99 (24), 1881-7
DOI 10.1093/jnci/djm249, PubMed 18073376

Publications 2006

Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD (2006)
[Treatment of hormone-resistant prostate cancer]
Tidsskr Nor Laegeforen, 126 (21), 2798-801
PubMed 17086220

Publications 2005

Hernes E, Harvei S, Glattre E, Gjertsen F, Fosså SD (2005)
High prostate cancer mortality in Norway: influence of Cancer Registry information?
APMIS, 113 (7-8), 542-9
DOI 10.1111/j.1600-0463.2005.apm_245.x, PubMed 16086825

Publications 2004

Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB (2004)
NY-ESO-1 protein expression and humoral immune responses in prostate cancer
Prostate, 59 (4), 440-7
DOI 10.1002/pros.20025, PubMed 15065093

Hernes E, Fosså SD, Berner A, Otnes B, Nesland JM (2004)
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
Br J Cancer, 90 (2), 449-54
DOI 10.1038/sj.bjc.6601536, PubMed 14735192

Publications 2003

Hernes E, Fosså SD, Skovlund E (2003)
Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour
Acta Oncol, 42 (7), 749-55
DOI 10.1080/02841860310014624, PubMed 14690161

Publications 1998

Otnes B, Hernes E, Fosså SD (1998)
[Prostate-specific antigen in the follow-up of conservatively treated prostatic cancer]
Tidsskr Nor Laegeforen, 118 (22), 3401-5
PubMed 9800488